Cypherpunk Technologies (CYPH) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
Annual Meeting of Shareholders scheduled for June 18, 2026, to be held virtually at 11:00 AM local time.
Shareholders can vote electronically using a control number or attend and vote at the virtual meeting.
Proxy materials, including the annual report and proxy statement, are available online for review.
Voting matters and shareholder proposals
Election of two persons nominated by the Board of Directors to the Board.
Non-binding advisory vote to approve compensation of named executive officers.
Ratification of EisnerAmper LLP as independent registered public accounting firm for fiscal year 2026.
Board recommends voting "FOR" all nominees and proposals.
Board of directors and corporate governance
Board of Directors has nominated two individuals for election at the annual meeting.
Latest events from Cypherpunk Technologies
- Q2 2026 profit surged on ZEC gains; lead cancer drug advanced to Phase 3 with FDA support.CYPH
Q2 2026 - Director elections, compensation, and auditor ratification passed with strong shareholder support.CYPH
AGM 2026 - $77.2M Q1 loss driven by ZEC volatility; Zcash holdings and clinical progress highlighted.CYPH
Q1 2026 - Virtual annual meeting to vote on directors, executive pay, and auditor, with strong governance focus.CYPH
Proxy filing - Returned to profitability in 2025 with strong ZEC gains, new capital, and clinical progress.CYPH
Q4 2025 - Shareholders approved key proposals including share increase, reverse split, and new equity plan.CYPH
AGM 2025 - Phase 2 trials for DKN-01 in gastric and colorectal cancer near key data readouts and expansion.CYPH
Piper Sandler 36th Annual Healthcare Conference - Sirexatamab improved response rates in CRC, especially in DKK1-high and VEGF-naive patients.CYPH
Study Result - Sirexatamab shows strong efficacy in GI cancer trials; FL-501 advances toward clinical studies.CYPH
43rd Annual J.P. Morgan Healthcare Conference 2025